Entacapone: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Entacapone. Educational only — not medical advice.
Labeled uses
Entacapone tablets, USP are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with Parkinson’s disease (see CLINICAL PHARMACOLOGY, Clinical Studies ). Entacapone tablets, USP effectiveness has not been systematically evaluated in patients with Parkinson’s disease who do not experience end-of-dose “wearing-off”.
Source: FDA labeling via NIH DailyMed (set 1fab63f2…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.